ALVR - 5 biotech names ready for a comeback- Barron's

Barron's spoke with investors and an analysts who focus on the biotech field to find names that are poised to make a comeback. Many biotech stocks have had a tough year so far. The SPDR Biotech ETF (NYSEARCA:XBI) is down 4.7% year-to-date. That compares to a 20.8% return in the same period for the S&P 500. The companies Barron's highlights are: Acceleron Pharma (NASDAQ:ALRN), Invitae (NYSE:NVTA), Sarepta Therapeutics (NASDAQ:SRPT), Compass Pathways (NASDAQ:CMPS), and AlloVir (NASDAQ:ALVR). Acceleron: The company's phase 3 candidate, sotatercept, to treat pulmonary arterial hypertension ("PAH"), is in a market that has "a ton of value in it," according to T. Rowe Price's Ziad Bakri. In 2017, Johnson & Johnson paid $30B to acquire the Swiss pharma Actelion, which was developing the PAH drug bosentan. The drug was approved by the FDA later that year as Tracleer and became a blockbuster for J&J. Invitae: Shares of the genetic

For further details see:

5 biotech names ready for a comeback- Barron's